Skip to content
1 min left
0% read
ENSCO Inc. logo

ENSCO Inc.

Mining Company
Endicott, New York, USA
Founded 1969
767
Share:

ENSCO, Inc.

ENSCO, Inc., and its wholly owned subsidiaries, represent a more than $190 million international technology enterprise with over 750 employees headquartered in the Washington, D.C., area. For more than 50 years, ENSCO has been providing leading-edge engineering, science, and advanced technology solutions to governments and private industries worldwide. ENSCO operates in the aerospace, national security, and surface transportation sectors.

ENSCO serves customers in cutting-edge, mission-critical environments where safety, security, reliability, and resilience are of paramount importance. ENSCO field offices and subsidiaries, representatives, and partnerships are located throughout the United States and around the world.

Frequently Asked Questions About ENSCO Inc.

ENSCO Inc. is a finance company. ENSCO, Inc

ENSCO, Inc., and its wholly owned subsidiaries, represent a more than $190+ million international technology enterprise with 750+ employees headquartered in the Washington, D.C.

, area. For more than 50 years, ENSCO has been providing leading-edge engineering, science and advanced technology solution.

ENSCO Inc. has been operating since 1969. You can verify their legitimacy through their official website and social media presence.

ENSCO Inc. operates in the finance sector of the cryptocurrency industry. Compare ENSCO Inc.

with other finance companies on Crypto News Navigator to evaluate services, features, and reputation before making your decision.

Before using ENSCO Inc., research their track record (operating since 1969), verify their regulatory compliance, read user reviews, and understand their fee structure. Never share your private keys with any service, and start with small amounts until you are comfortable with the platform.

Safety depends on multiple factors including regulatory compliance, security practices, and track record. ENSCO Inc. is based in Endicott, New York, USA, has been operating since 1969.

Always enable two-factor authentication, use strong passwords, and never store large amounts on any third-party platform.

ENSCO Inc. is based in Endicott, New York, USA, North America.

ENSCO Inc. was founded in 1969. The company currently has 767 employees.

ENSCO Inc. Details

ENSCO Inc. Tags

More About ENSCO Inc.

Work Model Details
Employees work from physical offices.

Latest from Academy

Blast Ecosystem Grew 400% in Six Months and Nobody Talked About It

Blast Ecosystem Grew 400% in Six Months and Nobody Talked About It

The Blast ecosystem has been crypto's most misunderstood narrative of 2026. While the market fixated on a 98.3% drawdown from all-time highs, less-publicized on-chain data tells a counterintuitive story. Three major protocol upgrades shipped since January 2025, 10% TVL growth appeared week-on-week in April, and 279,520 holders remain HODLing their positions on a chain the world has given up on.

7m
 Why Tokenlon's Revenue Doesn't Match Its Token Price

Why Tokenlon's Revenue Doesn't Match Its Token Price

DEX aggregation is "solved" in DeFi, right? 1inch, Jupiter, Paraswap have you covered. Except the data paints a different picture. Tokenlon quietly processes over $120 million in weekly trading volume and a 99.71% order success rate, yet remains shockingly absent from discussion in industry forums and panels. Either the market is correct and Tokenlon's fundamentals are not what we perceive, or a highly-traveled protocol has been willfully ignored.

Mia Halland logoMia HallandApr 26, 2026
8m
Sixty-Five Million in BioDAOs, BIO at One Cent

Sixty-Five Million in BioDAOs, BIO at One Cent

Bio Protocol's CEO recently revealed that PeptAI designed a new ADHD peptide candidate in 24 hours for roughly $1,500 in initial lab validation. While crypto traders focus on memecoins, Bio Protocol has quietly built a scientific funding platform backed by Pfizer Ventures, Binance Labs, and Arthur Hayes' Maelstrom Fund. The bio price trades at $0.031, down 96.5% from its all-time high of $0.889, despite $65M in combined BioDAO research funding and active clinical trials.

8m